Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUBT Curative Biotechnology	$0.01 -5.9%	$0.01	$0.00 ▼ $0.03	$11.34M	0.2	158,058 shs	30,114 shs
DYAI Dyadic International	$0.94 +3.9%	$0.95	$0.71 ▼ $2.20	$34.02M	0.89	81,603 shs	180,692 shs
KZR Kezar Life Sciences	$4.00 +1.0%	$4.27	$3.62 ▼ $9.18	$29.43M	0.65	38,361 shs	6,893 shs
MAAQ Mana Capital Acquisition	$3.67 +4.6%	$3.91	$5.35 ▼ $10.25	$29.82M	N/A	33,075 shs	27,070 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUBT Curative Biotechnology	+20.20%	+38.37%	+20.20%	-15.00%	-12.50%
DYAI Dyadic International	+3.99%	+14.49%	-17.75%	-9.98%	-37.61%
KZR Kezar Life Sciences	-1.00%	+2.06%	-8.12%	-1.98%	-41.73%
MAAQ Mana Capital Acquisition	0.00%	-1.08%	-16.12%	-13.41%	-38.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	3.4144 of 5 stars	3.5	5.0	0.0	0.0	2.7	3.3	0.0
KZR Kezar Life Sciences	3.5891 of 5 stars	3.2	0.0	0.0	4.6	1.7	2.5	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUBT Curative Biotechnology	0.00	N/A	N/A	N/A
DYAI Dyadic International	3.00	Buy	$6.00	538.30% Upside
KZR Kezar Life Sciences	2.33	Hold	$9.00	124.94% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CUBT, DYAI, MAAQ, and KZR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	KZR Kezar Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	$3.42M	9.94	N/A	N/A	($0.01) per share	-94.00
KZR Kezar Life Sciences	$7M	4.18	N/A	N/A	$12.53 per share	0.32
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUBT Curative Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	-$5.81M	-$0.19	N/A	N/A	N/A	-134.84%	-355.39%	-60.66%	11/11/2025 (Estimated)
KZR Kezar Life Sciences	-$83.74M	-$9.69	N/A	N/A	N/A	N/A	-63.51%	-52.13%	11/11/2025 (Estimated)
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CUBT, DYAI, MAAQ, and KZR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	DYAI Dyadic International	-$0.06	-$0.06	N/A	-$0.06	$0.60 million	$0.97 million
8/13/2025	Q2 2025	KZR Kezar Life Sciences	-$2.15	-$1.87	+$0.28	-$1.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUBT Curative Biotechnology	N/A	N/A	N/A
DYAI Dyadic International	5.40	2.02	2.02
KZR Kezar Life Sciences	0.03	7.29	7.29
MAAQ Mana Capital Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUBT Curative Biotechnology	N/A
DYAI Dyadic International	27.95%
KZR Kezar Life Sciences	67.90%
MAAQ Mana Capital Acquisition	68.44%

Insider Ownership

Company	Insider Ownership
CUBT Curative Biotechnology	N/A
DYAI Dyadic International	29.50%
KZR Kezar Life Sciences	9.30%
MAAQ Mana Capital Acquisition	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUBT Curative Biotechnology	4	1.01 billion	N/A	Not Optionable
DYAI Dyadic International	7	36.19 million	25.51 million	Optionable
KZR Kezar Life Sciences	60	7.32 million	6.64 million	Not Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable

CUBT, DYAI, MAAQ, and KZR Headlines

Recent News About These Companies

MANA Projects Continues Growth Trajectory with 2.5-Acre Land Acquisition Near Sarjapur Road

September 22, 2024 | news.webindia123.comN

Decentraland (CRYPTO: MANA)

April 10, 2024 | fool.com

Bernhard Capital sees acquisition potential for energy efficiency software business

September 26, 2023 | pehub.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUBT, DYAI, MAAQ, and KZR Company Descriptions

Curative Biotechnology OTCMKTS:CUBT

$0.01 0.00 (-5.88%)

As of 03:11 PM Eastern

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

Dyadic International NASDAQ:DYAI

$0.94 +0.04 (+3.90%)

As of 03:55 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Kezar Life Sciences NASDAQ:KZR

$4.00 +0.04 (+1.04%)

As of 03:55 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Mana Capital Acquisition NASDAQ:MAAQ

$3.67 +0.16 (+4.56%)

As of 08/26/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time